Makki Nader, Lilly Scott M
Department of Cardiology, Ohio State University Wexner Medical Center, Columbus, Ohio.
Clin Cardiol. 2018 Aug;41(8):1091-1096. doi: 10.1002/clc.22993. Epub 2018 Jul 18.
Chronic kidney disease (CKD) is associated with worse outcomes in high-surgical-risk patients undergoing transcatheter aortic valve replacement (TAVR). However, it is unclear whether this relationship is apparent in lower-surgical-risk patients. We sought to analyze existing literature to assess whether or not advanced CKD is associated with increased mortality or a greater incidence of adverse events (specifically major stroke, bleeding, and vascular complications). We searched PubMed and Embase (2008-2017) for relevant studies. Studies with <1 year follow-up and those not evaluating advanced CKD or outcomes post-TAVR were excluded. Our co-primary endpoints were the incidence of short-term mortality (defined as in-hospital or 30-day mortality) and long-term mortality (1 year). Our secondary endpoints included incidence of major stroke, life-threatening bleeding, and major vascular complications. Eleven observational studies with a total population of 10709 patients met the selection criteria. Among patients with CKD there was an increased risk of short- and long-term mortality in high-surgical-risk patients who underwent TAVR (hazard ratio [HR]: 1.51, 95% confidence interval [CI]: 1.22-1.88 and HR: 1.56, 95% CI: 1.38-1.77, respectively; P < 0.01). However, there was no association between CKD and mortality in low- to intermediate-risk patients (HR: 1.35, 95% CI: 0.98-1.84, P = 0.06 in short-term and HR: 1.08, 95% CI: 0.92-1.27, P = 0.34 in long-term). In low- to intermediate-risk TAVR patients, advanced CKD is not associated with increased mortality or poorer safety outcomes. These findings should be factored into the clinical decision-making process regarding TAVR candidacy.
慢性肾脏病(CKD)与接受经导管主动脉瓣置换术(TAVR)的高手术风险患者的不良预后相关。然而,在低手术风险患者中这种关系是否明显尚不清楚。我们试图分析现有文献,以评估晚期CKD是否与死亡率增加或不良事件(特别是重大卒中、出血和血管并发症)的发生率更高相关。我们在PubMed和Embase数据库中检索了2008年至2017年的相关研究。排除随访时间<1年以及未评估晚期CKD或TAVR术后结局的研究。我们的共同主要终点是短期死亡率(定义为住院期间或30天死亡率)和长期死亡率(1年)。次要终点包括重大卒中、危及生命的出血和重大血管并发症的发生率。11项观察性研究共纳入10709例患者,符合入选标准。在接受TAVR的高手术风险CKD患者中,短期和长期死亡风险增加(风险比[HR]分别为1.51,95%置信区间[CI]:1.22 - 1.88;HR为1.56,95%CI:1.38 - 1.77;P < 0.01)。然而,在低至中度风险患者中,CKD与死亡率之间无关联(短期HR:1.35,95%CI:0.98 - 1.84,P = 0.06;长期HR:1.08,95%CI:0.92 - 1.27,P = 0.34)。在低至中度风险的TAVR患者中,晚期CKD与死亡率增加或安全性较差的结局无关。这些发现应纳入关于TAVR候选资格的临床决策过程中。